CN112638907B - 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 - Google Patents

一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 Download PDF

Info

Publication number
CN112638907B
CN112638907B CN201980053697.XA CN201980053697A CN112638907B CN 112638907 B CN112638907 B CN 112638907B CN 201980053697 A CN201980053697 A CN 201980053697A CN 112638907 B CN112638907 B CN 112638907B
Authority
CN
China
Prior art keywords
form iii
crystalline form
mor
ray powder
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980053697.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN112638907A (zh
Inventor
王林
杜振兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112638907A publication Critical patent/CN112638907A/zh
Application granted granted Critical
Publication of CN112638907B publication Critical patent/CN112638907B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980053697.XA 2018-10-12 2019-10-11 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 Active CN112638907B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018111867437 2018-10-12
CN201811186743 2018-10-12
PCT/CN2019/110563 WO2020073985A1 (fr) 2018-10-12 2019-10-11 Structure cristalline d'un agoniste des récepteurs aux opiacés mu (mor) et son procédé de préparation

Publications (2)

Publication Number Publication Date
CN112638907A CN112638907A (zh) 2021-04-09
CN112638907B true CN112638907B (zh) 2022-04-12

Family

ID=70163634

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053697.XA Active CN112638907B (zh) 2018-10-12 2019-10-11 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法

Country Status (3)

Country Link
CN (1) CN112638907B (fr)
TW (1) TWI717859B (fr)
WO (1) WO2020073985A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017063509A1 (fr) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 Dérivé oxa spiro, son procédé de préparation, et ses applications dans des médicaments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2688403T1 (sl) * 2011-03-23 2017-08-31 Trevena, Inc. Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
UA124400C2 (uk) * 2017-04-14 2021-09-08 Цзянсу Хенжуй Медісін Ко., Лтд. Сіль агоніста опіоїдного рецептора (mor), кристалічна форма i його фумаратної солі та спосіб їх одержання

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017063509A1 (fr) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 Dérivé oxa spiro, son procédé de préparation, et ses applications dans des médicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R) 9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain;Xiao-Tao Chen 等;《Journal of Medicinal Chemistry》;20130924;第8019-8031页 *

Also Published As

Publication number Publication date
CN112638907A (zh) 2021-04-09
TWI717859B (zh) 2021-02-01
TW202016099A (zh) 2020-05-01
WO2020073985A1 (fr) 2020-04-16

Similar Documents

Publication Publication Date Title
CN110049980B (zh) 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法
US10189837B2 (en) Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
CN108727347B (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
EP3248983B1 (fr) Forme cristalline a de l'acide obéticholique et son procédé de préparation
CN109937200B (zh) 一种苯并呋喃类衍生物游离碱的晶型及制备方法
CN108884099B (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN112638906B (zh) 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
EP3360858A1 (fr) Procédé de production d'un dérivé aminopyrrolidine
CN112638907B (zh) 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
RU2779119C2 (ru) Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения
CN115448895A (zh) 一种沃替西汀前药的晶型、其制备方法和应用
TW201904972A (zh) 一種咪唑并異吲哚類衍生物游離鹼的晶型及其製備方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant